Published in Medical Device Law Weekly, October 18th, 2009
"In this study, we not only compare the individual expression status of 4 immunomarkers [estrogen receptor (ER), vimentin (Vim), carcinoembryonic antigen (CEA), and p16(INK4a)], but also evaluate whether p16(INK4a) adds value to the ER/Vim/CEA panel characteristics and performance in distinguishing between primary ECA and EMA. A...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.